#USA #New York #Investor Rights #Wolf Haldenstein #Aardvark Therapeutics

Investors Alert: Aardvark Therapeutics Shareholders

In recent developments, Wolf Haldenstein Adler Freeman & Herz LLP, a well-regarded law firm specializing in securities litigation, has made an essential announcement for investors who suffered losses in Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares. Shareholders who faced financial damage due to the company’s recent actions are encouraged to get in touch with the firm promptly.

Background of the Case

Wolf Haldenstein has initiated a securities class action lawsuit in the United States District Court for the Southern District of California on behalf of all individuals or entities that purchased Aardvark shares. This lawsuit centers around purchases made from the time of the company's Initial Public Offering (IPO) on February 13, 2025, up until May 14, 2026, marking a significant period of volatility for the stock.

Allegations against Aardvark

The lawsuit alleges serious misrepresentation and failure to disclose crucial information about the drug ARD-101. Investors were reportedly misled about the safety and efficacy of the drug, with claims that its clinical and commercial potential was exaggerated. The firm claims that the company’s public statements were materially false and misleading during the related period.

The situation escalated when Aardvark announced on February 27, 2026, that it was voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial, citing concerning cardiac observations. This announcement led to a drastic decline in stock price, dropping $7.02 per share (a staggering 56.2% decrease), underlining the urgency of the situation.

Why Contact Wolf Haldenstein?

Founded in 1888, Wolf Haldenstein is known for its dedicated representation of investors battling financial harm stemming from misleading corporate behavior. With more than 125 years of experience, the firm has built a solid reputation and has a proven track record in the field of securities litigation.

The firm is welcoming any investors who may have been impacted by the situation or who possess information relevant to the ongoing investigation to come forward. It’s essential for those affected to understand that contacting the firm incurs no costs or obligations, encouraging a widespread outreach for potential claimants.

Contact Information

Investors wishing to inquire further can contact Wolf Haldenstein directly through the following channels:

• - Phone: (800) 575-0735 or (212) 545-4774
• - Email: [email protected]
• - Contact Person: Gregory Stone, Director of Case and Financial Analysis

The firm emphasizes the necessity of acting quickly, as the deadline to be appointed as a lead plaintiff is on October 13, 2026. This pivotal moment allows impacted shareholders a chance to assert their rights and seek compensation for their financial losses stemming from investments in Aardvark.

In conclusion, as legal proceedings take shape, it remains crucial for all affected investors to stay informed and connected, reinforcing the essential role of legal expertise in securing both clarity and justice in the often tumultuous world of stock investments.